Division News

The recipients of the Department of Medicine faculty Excellence in Education Awards have been announced.

The Duke UNC-Chapel Hill Immunotherapy Training Grant (DUNC-IMTG) is accepting applications for the 2020-2021 admission cycle. DUNC-IMTG is a combined training program from the University of North Carolina at Chapel Hill and Duke University that will focus on training individuals in translational and/or clinical research focusing on tumor immunology and cellular immunotherapy. Applications are due June 15, 2020.

Congratulations to the Department of Medicine faculty who are being recognized by the School of Medicine for their leadership, service, mentoring, and professionalism.

Keith Sullivan, MD, the James B. Wyngaarden Distinguished Professor of Medicine (Hematologic Malignancies and Cellular Therapy), is the recipient of the American Society for Transplantation and Cellular Therapy's 2020 Lifetime Achievement Award.

David Bartlett, PhD, assistant professor of medicine (Medical Oncology), has been selected to receive a $150,000 clinical-junior-faculty-level 2020 ASH Scholar Award by the American Society of Hematology

Eight faculty from the Department of Medicine have been selected for the 2020 Duke Clinical Leadership Program.

Two faculty from the Department of Medicine have been recognized with awards from the American Academy of Hospice and Palliative Medicine (AAHPM).

Nelson Chao, MD, MBA, has served as the chief for the Division of Cellular Therapy since 1996, and for the expanded Division of Hematologic Malignancies & Cellular Therapy since 2013. At the same time, Dr. Chao also has served as leader of the Hematologic Malignancies & Cellular Therapy Research Program for the Duke Cancer Institute (DCI). 

A study led by Mitchell Horwitz, MD, professor of medicine (Hematologic Malignancies and Cellular Therapy), has found that umbilical cord blood stem cells that are cultured and expanded outside the body before being used for bone marrow transplant in adult blood cancer patients appear safe and restore blood count recovery faster than standard cord blood. The findings advance efforts to improve cord blood use among adults who have been diagnosed with blood cancers. 

​Micah A. Luftig, PhD, associate professor of molecular genetics and microbiology and medicine (Hematologic Malignancies and Cellular Therapy), has been named a Fellow of the American Association for the Advancement of Science (AAAS).